IBA Spearheads EU Project for Cancer Treatment Isotope

Ion Beam Applications SA IBA (GB:0GZK) has released an update.

IBA, a leader in particle accelerator technology, has announced the launch of the Accelerate.EU project aimed at establishing a stable, EU-wide supply chain for Astatine-211, an innovative alpha-emitting isotope for cancer treatment. With a budget of EUR 16 million, half funded by the European Commission, the project unites 17 institutions across 9 countries to enhance access to advanced cancer therapies. IBA’s contribution to the project includes the development of a new alpha-machine cyclotron, reinforcing its position in the market.

For further insights into GB:0GZK stock, check out TipRanks’ Stock Analysis page.